These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Lyndiol (1 mg)--evaluation of a new low dose oral contraceptive.
    Author: Banerjee SK.
    Journal: Antiseptic; 1977 Sep; 74(9):531-3. PubMed ID: 12281247.
    Abstract:
    The combined oral contraceptive (OC) has become one of the most effective methods of controlling India's staggering population growth. Even the less literate of Indian women have accepted the combined OC with considerable enthusiasm, because they understand that it is a method with a 100% guarantee. As progestogen sensitivity is much more marked than sensitivity to estrogens in India, indicated by the incidence of chloasma and amenorrhea, a trial of a new low dose OC was conducted at the Family Planning Welfare Center of Medical College, Calcutta, India. Lyndiol, 1 mg (ethinylestradiol .05 mg and lynestrenol 1 mg) has low progestogen potency. The trial was initiated in July 1973 and has involved 90 patients over 375 cycles. The patients were selected from married women attending the Family Planning Welfare Center for contraceptive advice. The amount of menstrual flow was unaltered in 81 cases and in 10% of cases there was a reduction of flow as compared with pretreatment menstruation. This compared very favorably with highly progestogenic contraceptives that show a reduction of menstrual flow in over 50% of patients. Only 2 patients complained of breakthrough bleeding or spotting in early cycles. 9 patients (10%) complained of nausea and vomiting in early cycles; 5 patients complained of failure of a withdrawal bleeding in early cycles. Some weight gain was observed in 16 patients (17.7%); 4 patients noted a weight loss. Only 6 patients complained of a headache and 5 of breast engorgement. In this study, 6 patients (6.6%) showed a mean rise of systolic blood pressure of 10 mm and a diastolic pressure of 4 mm. The major risk associated with estrogen/progestogen combination is thromboembolism. In India its incidence is rather low. This trial with Lyndiol 1 mg corroborates this since no thromboembolic occurrences were noted. In sum, Lyndiol (1 mg) is an ideal OC, which is available for Indian mothers with a minimum of side effects.
    [Abstract] [Full Text] [Related] [New Search]